Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HWH340 in Advanced Solid Tumors
NCT03415659Phase 1Unknown
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hwh340 in solid tumor (advanced stage), sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute. Primary endpoints: Maximum Tolerated Dose, Recommended Dose and 2 more. Status: unknown.
02
Drugs
hwh340
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03415659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415659.